3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
11
Recurrence
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Burkitt Lymphoma
8
Lymphoma, Follicular
5
Lymphoma
2
Leukemia
2
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Interventions
blinatumomab
5
midostaurin
2
Azacitidine
2
venetoclax
1
tisagenlecleucel
1
siremadlin
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
fludarabine phosphate
1
fludarabine
1
Zoledronic Acid
1
Vitamin D
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Midazolam
1
Idarubicin
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium
1
CD3 Complex
1
Anthracyclines
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm, Residual
×
tisagenlecleucel
×
Clear all
NCT03876769
2026-06-02
CASSIOPEIA
Novartis
Phase 2
Active not recruiting
121 enrolled